(opens in a new window)

Michael C. Milone, MD/PhD

Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

  • Staff Physician, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania
  • Associate Vice Chair for Profession Development and Academic Affairs, Department of Pathology and Laboratory Medicine, Perelman School of Medicine,

Department: Pathology and Laboratory Medicine


Graduate Group Affiliations


Contact Information

3400 Spruce Street 7103 Founders Pavilion
Philadelphia, PA 19104
Office: 215-662-6575
Fax: 215-662-7529
Email: milone@pennmedicine.upenn.edu


I3H Keywords

  • Autoimmunity
  • Cancer Immunology and Immunotherapy

Publications

Pubmed Link


Links


Education

  • B.S (Chemical Biology)
    Stevens Institute of Technology, 1993
  • M.D. (Medical Doctor)
    UMDNJ- New Jersey Medical School, 1999
  • Ph.D (Experimental Pathology/ Immunology)
    UMDNJ - Graduate School of Biomedical Sciences, 1999

Post-Graduate Training

  • Internship, Internal Medicine
    Hospital of the University of Pennsylvania, 1999 - 2000
  • Resident, Clinical Pathology
    Hospital of the University of Pennsylvania, 2000 - 2002
  • Chief Resident, Division of Laboratory Medicine
    Hospital of the University of Pennsylvania, 2001 - 2002
  • Clinical Fellowship, Blood Banking and Transfusion Medicine
    Hospital of the University of Pennsylvania, 2002 - 2003
  • Postdoctoral. Research Fellow, Translational Research Program
    Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, 2003 - 2007
  • Clinical Fellow, Clinical Chemistry and Laboratory Toxicology
    Hospital of the University of Pennsylvania, 2004 - 2007

Certifications

  • Clinical Pathology, American Board of Pathology, 2002

Description of Clinical Expertise

Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis

Description of Research Expertise

Research in my laboratory is focused on T cell biology and applications of genetically-engineered T cells to the treatment of disease.

Active research projects in my laboratory include:

1) Developing chimeric antigen receptors (CARs) and other engineering approaches for enhancing the function and improved safety of adoptive T cell therapy.

2) Developing and applying synthetic immunoreceptors to the treatment of immune-mediated disease.

3) Exploring the role of co-stimulatory signals in directing T cell metabolism and the way this metabolism affects T cell function within tumors.


Description of ITMAT Expertise

My laboratory is focused upon developing methods to use the immune system to treat cancer. Active research includes 1) exploring the mechanical properties of artificial adhesion substrates used in T cell culture and their influence on T cell biology, 2) development of artificial antigen receptors and signaling systems for control of T cell specificity

Selected Publications

  • Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I. J., Gabrielli, G., Nasta, S. D., Porazzi, P., Landsburg, D. J., Gerson, J. N., Carter, J., Barta, S. K., Yelton, R., Pajarillo, R., Patel, V., White, G., Ballard, H. J., Weber, E., Napier, E., Chong, E. R., Fraietta, J. A., Garfall, A. L., Porter, D. L., Milone, M. C., O'Connor, R., Schuster, S. J., Ruella, M. : Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines Blood Adv 8(3) : 653-666, February 2024
  • Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox JJ, Scholler J, Marcellus B, Allman D, Fraietta JA, Samelson-Jones B, Milone MC, Monos D, Garfall AL, Naji A, Bhoj VG. : Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies Cell Rep Med 4 : 101336, Dec 2023
  • Grover P, Nunez-Cruz S, Leferovich J, Wentz T, Bagchi A, Milone MC, Greene MI. : F77 antigen is a promising target for adoptive T cell therapy of prostate cancer Biochem Biophys Res Commun 680 : 51-60, Nov 2023
  • Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. : Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells Nat Biotechnol 41(9) : 1229-1238, Sept 2023
  • Glisovic-Aplenc, T., Diorio, C., Chukinas, J. A., Veliz, K., Shestova, O., Shen, F., Nunez-Cruz, S., Vincent, T. L., Miao, F., Milone, M. C., June, C. H., Teachey, D. T., Tasian, S. K., Aplenc, R., Gill, S. : CD38 as a pan-hematologic target for chimeric antigen receptor T cells Blood Adv 7(16) : 4418-4430, Aug 2023
  • Thakrar AP, Faude S, Perrone J, Milone MC, Lowenstein M, Snider CK, Spadaro A, Delgado MK, Nelson LS, Kilaru AS. : Association of Urine Fentanyl Concentration With Severity of Opioid Withdrawal Among Patients Presenting to the Emergency Department J Addict Med 17(4) : 447-453, July-Aug 2023
  • Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA. : Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy Blood Cancer Discov 4 : 118-133, Mar 2023
  • Dhodapkar KM, Cohen AD, Kaushal A, Garfall AL, Manalo RJ, Carr AR, McCachren SS, Stadtmauer EA, Lacey SF, Melenhorst JJ, June CH, Milone MC, Dhodapkar MV. : Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discov. Aug 2022 Notes: OF1-OF12. doi: 10.1158/2643-3230.BCD-22-0018. Online ahead of Print.
  • Ghassemi, Saba, Durgin, Joseph S., Nunez-Cruz, Selene, Patel, Jai, Leferovich, John, Pinzone, Marilia, Shen, Feng, Cummins, Katherine D., Plesa, Gabriela, Cantu, Vito Adrian, Reddy, Shantan, Bushman, Frederic D., Gill, Saar I., O’Doherty, Una, O’Connor, Roddy S., Milone, Michael C. : Rapid manufacturing of non-activated potent CAR T cells Nature Biomedical Engineering 2022
  • Ellis, G. I., Coker, K. E., Winn, D. W., Deng, M. Z., Shukla, D., Bhoj, V., Milone, M. C., Wang, W., Liu, C., Naji, A., Duran-Struuck, R., Riley, J. L. : Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque Cell Rep Med 3(5) : 100614, 2022